NSTG NanoString Technologies

NanoString Announces the University of Oxford Selected as the Winning Recipient in GeoMx Digital Spatial Profiler Grant Program

NanoString Announces the University of Oxford Selected as the Winning Recipient in GeoMx Digital Spatial Profiler Grant Program

DSP to be Applied to Transplant Research of Regulatory T Cell Therapy in Kidney Transplantation

SEATTLE, Oct. 04, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the University of Oxford has been selected as the winning recipient of a grant for a GeoMx™ Digital Spatial Profiler (DSP) as part of the DSP grant program. The grant program included more than 100 submissions from around the world.

“We are honored to announce that Dr. Fadi Issa from University of Oxford has been selected as the winning recipient of a grant for our GeoMx Digital Spatial Profiler,” said Chad Brown, senior vice president of sales and marketing of NanoString Technologies. “The University of Oxford is home to an internationally recognized organ transplant program with a strong research focus on transplant immunology. NanoString is excited to engage the transplant community with our unique solution for spatial genomics.”

According to Dr. Issa, “Spatial genomics has the potential to make a major impact in transplantation research. Digital Spatial Profiling will allow us to collect comprehensive biological information from our precious tissue samples, including highly informative topographic data,” stated Fadi Issa, MA, BMBCh, MSc, PhD, FRCS, Principal Investigator at the Transplantation Research Immunology Group (TRIG), Nuffield Department of Surgical Sciences, University of Oxford.  “We’re currently leading a clinical trial of a novel cellular therapy, regulatory T cells in renal transplantation, and we believe DSP will be invaluable in understanding patient response and guiding future decisions in this important program.”

NanoString's GeoMx Digital Spatial Profiling technology enables the precise quantification of 10’s to 1000’s of proteins and/or RNA targets mapped to their location within a heterogeneous tissue. NanoString and its collaborators have presented GeoMx DSP data in more than a dozen abstracts at major scientific meetings, demonstrating the utility of DSP profiling to address a wide range of biological questions in Formalin Fixed Paraffin Embedded (FFPE) tissues.

The GeoMx Digital Spatial Profiler is currently in development and is expected to be commercially available in mid-2019. Today, Digital Spatial Profiling technology can be accessed through NanoString’s Technology Access Program (TAP).  To date, over 40 customers have completed more than 55 TAP projects and processed over 1000 samples.  The results from these studies highlight the performance of DSP in at least ten abstracts presented at major scientific meetings and several publications in press.

Interested parties can learn more about DSP by visiting .

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit .

The NanoString logo, NanoString, NanoString Technologies, GeoMx, nCounter and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.

Contact:

Doug Farrell

Vice President, Investor Relations & Corporate Communications



Phone: 206-602-1768

EN
04/10/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NanoString Technologies

 PRESS RELEASE

NanoString Reports Inducement Grants Under Nasdaq Listing Rules

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 10 new employees. In accordance with Nasdaq Listing Rule 5635(c)(4), on December 6, 2023, the Compensation and Human Capital Committee of NanoString’s Board of Directors approved the grant of, in the aggregate, 34,925 restricted stock units, or RSUs, as material inducements to the 10 employees entering into employment with NanoString. One-third of the R...

 PRESS RELEASE

NanoString to Webcast Presentation from 42nd Annual J.P. Morgan Health...

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 42nd annual J.P. Morgan healthcare conference, being held January 8-11, 2024. Brad Gray, president and chief executive officer, is scheduled to present on Wednesday, January 10, at 5:15pm ET. Interested parties can access the live webcast from the investor section of the company’s website at . The webcast replay will be available one hour after the conc...

 PRESS RELEASE

NanoString Comments on Delaware District Court Verdict

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, commented on the November 17th verdict of a jury in the U.S. District Court for the District of Delaware finding that NanoString GeoMx® Digital Spatial Profiler products infringe patents licensed to 10x Genomics and awarding approximately $31 million in damages, consisting of approximately $25 million of lost profits and a $6 million royalty. “We respectfully disagree with the jury’s verdict, which we will seek to have overturned or amend...

 PRESS RELEASE

NanoString to Webcast Presentations from Upcoming Healthcare Conferenc...

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast presentations from two upcoming healthcare conferences. Stifel 2023 Healthcare Conference Tuesday, November 14th Tom Bailey, NanoString’s chief financial officer, and Doug Farrell, VP of Investor Relations, will participate in a fireside discussion hosted by Stifel analyst Dan Arias at 9:45am ET. Jefferies London Healthcare Conference Thursday, November 16th Tom Bailey, Nano...

 PRESS RELEASE

NanoString Technologies Releases Operating Results for Third Quarter o...

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2023. The Company also announced it had reached agreement with holders to exchange approximately $216 million, or 94%, principal amount of its Convertible Notes for new Senior Secured Notes due September 1, 2026 and common stock warrants. “The last few months have been extraordinarily productive for our team. During the third quarter, we delivered record revenue whi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch